BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kawanaka M, Nishino K, Kawamoto H, Haruma K. Hepatitis B: Who should be treated?-managing patients with chronic hepatitis B during the immune-tolerant and immunoactive phases. World J Gastroenterol 2021; 27(43): 7497-7508 [PMID: 34887645 DOI: 10.3748/wjg.v27.i43.7497] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Li H, Lin X, Liu L, Qin L, Zheng Y, Liu X, Wei X, Liang S, Liu Y, Zhang J, Chen X, Cao Z. Low Level of Serum Immunoglobulin G Is Beneficial to Clinical Cure Obtained With Pegylated Interferon Therapy in Inactive Surface Antigen Carriers. Front Immunol 2022;13:864354. [DOI: 10.3389/fimmu.2022.864354] [Reference Citation Analysis]
2 Wu C. Silicon Nanowires Length and Numbers Dependence on Sensitivity of the Field-Effect Transistor Sensor for Hepatitis B Virus Surface Antigen Detection. Biosensors 2022;12:115. [DOI: 10.3390/bios12020115] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]